Development of water soluble derivatives of cis-3, 4', 5-trimethoxy-3'- aminostilbene for optimization and use in cancer therapy

Investigational New Drugs

Volumn 27, Issue 1, 2009, Pages 41-52

  Durrant, David E ^a   Richards, Joanna ^a   Tripathi, Ashutosh ^b   Kellogg, Glen E ^b   Marchetti, Paolo ^c   Eleopra, Marco ^c   Grisolia, Giuseppina ^c   Simoni, Daniele ^c   Lee, Ray M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

Bevacizumab; Mitotic arrest; Prodrug; Stilbene; Tubulin inhibitor

Indexed keywords

1 [5 [2 (3,5 DIMETHOXYPHENYL)VINYL] 2 METHOXYPHENYL] 3 (2 MORPHOLIN 4 YLETHYL)UREA; 3,4',5 TRIMETHOXY 3' AMINOSTILBENE; AURORA A KINASE; BEVACIZUMAB; CYCLIN DEPENDENT KINASE 1; PRODRUG; PROTEIN KINASE B; PROTEIN P53; STILBENE DERIVATIVE; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; 1 (5 (2 (3,5 DIMETHOXYPHENYL)VINYL) 2 METHOXYPHENYL) 3 (2 MORPHOLIN 4 YLETHYL)UREA; 1-(5-(2-(3,5-DIMETHOXYPHENYL)VINYL)-2-METHOXYPHENYL)-3-(2-MORPHOLIN-4-YLETHYL)UREA; ANGIOGENESIS INHIBITOR; ANTIMITOTIC AGENT; CARBANILAMIDE DERIVATIVE; CIS 3,4',5 TRIMETHOXY 3' AMINOSTILBENE; CIS-3,4',5-TRIMETHOXY-3'-AMINOSTILBENE; MORPHOLINE DERIVATIVE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TOXICITY; CANCER THERAPY; CARDIOTOXICITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; MAXIMUM TOLERATED DOSE; MICROTUBULE; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT; ANIMAL; CELL PROLIFERATION; CHEMISTRY; COMPUTER AIDED DESIGN; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; NUDE MOUSE; SOLUTION AND SOLUBILITY; SYNTHESIS; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIMITOTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTER-AIDED DESIGN; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; MICE; MICE, NUDE; MICROTUBULES; MORPHOLINES; PHARMACEUTICAL SOLUTIONS; PHENYLUREA COMPOUNDS; PRODRUGS; STILBENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 62749191543     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9139-y     Document Type: Article

References (40)

1. D Neri R Bicknell 2005 Tumour vascular targeting Nat Rev Cancer 5 6 436 446 (Pubitemid 40791486)
2. J Folkman T Browder J Palmblad 2001 Angiogenesis research: guidelines for translation to clinical application Thromb Haemost 86 1 23 33 (Pubitemid 32663933)
3. J Folkman 2007 Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6 4 273 286 (Pubitemid 46505878)
4. TS Collins HI Hurwitz 2005 Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer Semin Oncol 32 1 61 68 (Pubitemid 40250127)
5. T Shih C Lindley 2006 Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies Clin Ther 28 11 1779 1802 (Pubitemid 46038527)
6. JA Garcia BI Rini 2007 Recent progress in the management of advanced renal cell carcinoma CA Cancer J Clin 57 2 112 125 (Pubitemid 46535711)
7. BI Rini 2007 Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions Clin Cancer Res 13 4 1098 1106 (Pubitemid 46424048)
8. LH O'Hanlon 2005 Taking down tumors: vascular disrupting agents entering clinical trials J Natl Cancer Inst 97 17 1244 1245 (Pubitemid 41535361)
9. DW Siemann DJ Chaplin MR Horsman 2004 Vascular-targeting therapies for treatment of malignant disease Cancer 100 12 2491 2499 (Pubitemid 38715753)
10. PE Thorpe 2004 Vascular targeting agents as cancer therapeutics Clin Cancer Res 10 2 415 427 (Pubitemid 38173977)
11. A Dowlati 2002 A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer Cancer Res 62 12 3408 3416 (Pubitemid 34651387)
12. JP Stevenson 2003 Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow J Clin Oncol 21 23 4428 4438 (Pubitemid 46621821)
13. GJ Rustin 2003 Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results J Clin Oncol 21 15 2815 2822 (Pubitemid 46621828)
14. HL Anderson 2003 Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate J Clin Oncol 21 15 2823 2830 (Pubitemid 46621829)
15. LV Beerepoot 2006 Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors J Clin Oncol 24 10 1491 1498 (Pubitemid 46638769)
16. M Roberti 2003 Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents J Med Chem 46 16 3546 3554 (Pubitemid 36909831)
17. TM Cao 2008 Stilbene derivatives that are colchicine site microtubule inhibitors have anti-leukemic activity and minimal systemic toxicity Am J Hematol 83 5 390 397 (Pubitemid 351614753)
18. Durrant D et al (2008) cis-3, 4', 5-trimethoxy-3'-aminostilbene disrupts tumor vascular perfusion without damaging normal organ perfusion. Cancer Chemother Pharmacol DOI 10.1007/s00280-008-0726-6
19. GM Tozer 1999 Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues Cancer Res 59 7 1626 1634 (Pubitemid 29160136)
20. C Malcontenti-Wilson 2001 Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model Clin Cancer Res 7 4 1052 1060 (Pubitemid 32708745)
21. YL Leu SR Roffler JW Chern 1999 Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT) J Med Chem 42 18 3623 3628 (Pubitemid 29445095)
22. R Lougerstay-Madec 1998 Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard Anticancer Drug Des 13 8 995 1007 (Pubitemid 29178770)
23. GM Tozer C Kanthou BC Baguley 2005 Disrupting tumour blood vessels Nat Rev Cancer 5 6 423 435 (Pubitemid 40791485)
24. P Thomson 2006 Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4 Mol Cancer Ther 5 11 2886 2894 (Pubitemid 44849016)
25. M Bakker 1998 Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients Br J Cancer 77 1 139 146 (Pubitemid 28029786)
26. JI Kuratsu 2000 Phase II trial of pre-irradiation KRN8602 (MX2) in malignant glioma patients J Neurooncol 48 2 145 149
27. Y Takemoto 1999 A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia The KRN8602 Leukemia Study Group. Int J Hematol 70 1 20 25
28. J Kuratsu 1999 A phase II study of KRN8602(MX2), a novel morpholino anthracycline derivative, in patients with recurrent malignant glioma J Neurooncol 42 2 177 181 (Pubitemid 29322154)
29. DH Lau GE Duran BI Sikic 1992 Characterization of covalent DNA binding of morpholino and cyanomorpholino derivatives of doxorubicin J Natl Cancer Inst 84 20 1587 1592
30. S Zhang P Hemmerich F Grosse 2007 Centrosomal localization of DNA damage checkpoint proteins J Cell Biochem 101 2 451 465 (Pubitemid 46698878)
31. M Castedo 2004 The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe Oncogene 23 25 4353 4361 (Pubitemid 38850414)
32. Durrant D et al (2008) Mechanism of cell death induced by cis-3, 4', 5-trimethoxy-3'-aminostilbene in ovarian cancer. Gynecol Oncol PMID: 18433847
33. K Yoshida H Liu Y Miki 2006 Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor suppressor in the apoptotic response to DNA damage J Biol Chem 281 9 5734 5740 (Pubitemid 43847672)
34. S Komiyama 2004 Potentiality of DNA-dependent protein kinase to phosphorylate Ser46 of human p53 Biochem Biophys Res Commun 323 3 816 822 (Pubitemid 39243392)
35. B Cecchinelli 2006 Ser58 of mouse p53 is the homologue of human Ser46 and is phosphorylated by HIPK2 in apoptosis Cell Death Differ 13 11 1994 1997 (Pubitemid 44542411)
36. C Rinaldo 2007 MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis Mol Cell 25 5 739 750 (Pubitemid 46341925)
37. E Oricchio 2006 ATM is activated by default in mitosis, localizes at centrosomes and monitors mitotic spindle integrity Cell Cycle 5 1 88 92
38. C Ditchfield 2003 Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores J Cell Biol 161 2 267 280 (Pubitemid 36529846)
39. CJ Morrow 2005 Bub1 and aurora B cooperate to maintain BubR1-mediated inhibition of APC/CCdc20 J Cell Sci 118 Pt 16 3639 3652 (Pubitemid 41309411)
40. Y Shaked 2006 Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors Science 313 5794 1785 1787 (Pubitemid 44454154)